Effect of the new specific bradycardia agent AQ-A39 (falipamil) on coronary collateral blood flow in dogs. J Cardiovasc Pharmacol 1987 Jul;10(1):123-7
Date
07/01/1987Pubmed ID
2441148DOI
10.1097/00005344-198707000-00017Scopus ID
2-s2.0-0023190390 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
The effect of two doses (0.5 and 1.0 mg/kg i.v.) of a new specific bradycardic agent, AQ-A39 (5,6-dimethoxy-2-[3- [( alpha- (3,4,-dimethoxy)phenylethyl]methyl-amino)propyl]phthalimidine hydrochloride), on three indices of collateral function--retrograde pressure, retrograde flow, and tissue blood flow (radioactive microspheres)--was studied in anesthetized dogs following acute occlusion of the left anterior descending coronary artery. AQ-A39 produced a significant (p less than 0.05) dose-related decrease in heart rate without any other hemodynamic changes. Retrograde flow and subendocardial blood flow were significantly increased by the lower dose of AQ-A39, whereas retrograde pressure, retrograde flow, and midmyocardial and subendocardial flow were increased by the higher dose. Atrial pacing to the control heart rate eliminated the beneficial effects of AQ-A39 on collateral function. These results suggest that an increase in collateral perfusion may be one mechanism by which AQ-A39 alleviates myocardial ischemia.
Author List
Gross GJ, Daemmgen JWMESH terms used to index this publication - Major topics in bold
AnimalsBradycardia
Cardiovascular Agents
Collateral Circulation
Coronary Circulation
Dogs
Female
Hemodynamics
Isoindoles
Male
Phthalimides
Regional Blood Flow
